Regencell Bioscience Total Debt vs. Book Value Per Share

RGC Stock  USD 6.32  0.33  5.51%   
Based on the measurements of profitability obtained from Regencell Bioscience's financial statements, Regencell Bioscience Holdings is yielding more profit at this time then in previous quarter. It has a moderate odds of reporting better profitability numbers in January. Profitability indicators assess Regencell Bioscience's ability to earn profits and add value for shareholders. At present, Regencell Bioscience's Operating Cash Flow Sales Ratio is projected to increase slightly based on the last few years of reporting. At present, Regencell Bioscience's Net Income Per Share is projected to slightly decrease based on the last few years of reporting. The current year's Income Quality is expected to grow to 3.65, whereas Accumulated Other Comprehensive Income is forecasted to decline to (48.1 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.981.11
Fairly Down
Pretty Stable
Net Profit Margin0.05460.0408
Significantly Up
Pretty Stable
Operating Profit Margin0.120.0988
Fairly Up
Slightly volatile
Pretax Profit Margin0.09060.0778
Fairly Up
Very volatile
For Regencell Bioscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Regencell Bioscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Regencell Bioscience Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Regencell Bioscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Regencell Bioscience Holdings over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.33)
Return On Assets
(0.28)
Return On Equity
(0.43)
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Regencell Bioscience Book Value Per Share vs. Total Debt Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Regencell Bioscience's current stock value. Our valuation model uses many indicators to compare Regencell Bioscience value to that of its competitors to determine the firm's financial worth.
Regencell Bioscience Holdings is rated below average in total debt category among its peers. It is rated below average in book value per share category among its peers . The ratio of Total Debt to Book Value Per Share for Regencell Bioscience Holdings is about  135,666 . At present, Regencell Bioscience's Book Value Per Share is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regencell Bioscience's earnings, one of the primary drivers of an investment's value.

Regencell Total Debt vs. Competition

Regencell Bioscience Holdings is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 364.55 Million. Regencell Bioscience adds roughly 85,741 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Valuation  Workforce  Capitalization  Revenue

Regencell Book Value Per Share vs. Total Debt

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Regencell Bioscience

Total Debt

 = 

Bonds

+

Notes

 = 
85.74 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Regencell Bioscience

Book Value per Share

 = 

Common Equity

Average Shares

 = 
0.63 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Regencell Book Value Per Share Comparison

Regencell Bioscience is currently under evaluation in book value per share category among its peers.

Regencell Bioscience Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Regencell Bioscience, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Regencell Bioscience will eventually generate negative long term returns. The profitability progress is the general direction of Regencell Bioscience's change in net profit over the period of time. It can combine multiple indicators of Regencell Bioscience, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-45.8 K-48.1 K
Operating Income-4.7 M-4.5 M
Income Before Tax-4.4 M-4.1 M
Total Other Income Expense Net373.5 K392.2 K
Net Loss-4.4 M-4.1 M
Income Tax Expense312.1 K296.5 K
Net Loss-4.4 M-4.6 M
Net Loss-6.7 M-6.4 M
Change To Netincome2.3 M2.2 M
Net Income Per Share(0.33) 0.72 
Income Quality 0.92  3.65 
Net Income Per E B T 0.99  0.53 

Regencell Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Regencell Bioscience. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Regencell Bioscience position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Regencell Bioscience's important profitability drivers and their relationship over time.

Use Regencell Bioscience in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regencell Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regencell Bioscience will appreciate offsetting losses from the drop in the long position's value.

Regencell Bioscience Pair Trading

Regencell Bioscience Holdings Pair Trading Analysis

The ability to find closely correlated positions to Regencell Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regencell Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regencell Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regencell Bioscience Holdings to buy it.
The correlation of Regencell Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regencell Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regencell Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regencell Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Regencell Bioscience position

In addition to having Regencell Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recreation Thematic Idea Now

Recreation
Recreation Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Recreation theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out Your Equity Center.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
To fully project Regencell Bioscience's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Regencell Bioscience at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Regencell Bioscience's income statement, its balance sheet, and the statement of cash flows.
Potential Regencell Bioscience investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Regencell Bioscience investors may work on each financial statement separately, they are all related. The changes in Regencell Bioscience's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regencell Bioscience's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.